- Ubrogepant during prodromal phase of migraine reduces common symptoms.
- Study involved 477 participants.
- Ubrogepant outperformed placebo in relieving symptoms.
- No serious adverse events reported.
- Common side effects were mild and included nausea, fatigue, and dizziness.
Source: Nature Medicine
